Petzold 2002.

Methods	Parallel‐group RCTs (3 RCTs reported together in abstract)
Participants	Study 3034: 78 participants; Study 3062: 145 participants; Study 3021: 240 participants with allergic conjunctivitis
Interventions	Two treatment arms: azelastine 0.05%; placebo. Duration of treatment 14 or 28 days.
Outcomes	Investigators' assessment of ocular symptoms (itching and redness) using a 4‐point scale (0 = none, 3 = severe) Time scale: day 0, 3, and 14 of treatment
Country	Europe
Number randomised, gender (male:female)	Study 3034: 78 participants (number of participants in each arm uncertain) randomised Study 3062: 145 participants (number of participants in each arm uncertain) Study 3021: 240 participants (number of participants in each arm uncertain). Gender not stated (abstract)
Age mean (SD), median, range	Age range 4‐12 years
Notes	Not reported when study was conducted. Source of funding not stated. Declaration of interest by the authors was not stated
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Only abstract available
Allocation concealment (selection bias)	Unclear risk	Only abstract available
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Only abstract available
Selective reporting (reporting bias)	Unclear risk	Only abstract available
Other bias	Unclear risk	Only abstract available
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Only abstract available
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Only abstract available